Print this page    •   Back to Web version of article

Gilead Provides Expanded Access Program for Tenofovir

March 2001

Gilead Sciences, the developers of a new nucleotide analogue, tenofovir (PMPA), started a small expanded access program in January.

The most important use of this drug, for now, will probably be in people who have developed resistance to several of the NRTI drugs, like d4T (Zerit) and AZT (Retrovir), and need something new to shore up their combination therapy. It is less clear whether the drug will compensate for protease inhibitor failure. The initial program will begin small and expand during 2001 as drug supplies increase.

To qualify, people must have all of the following:

To register patients in the program, physicians should call 800-GILEAD-5 (800-445-3235).

As more drug supplies become available, the criteria to qualify will change.


Back to the Project Inform Perspective March 2001 contents page.




This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art5556.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.